Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-04

AUTHORS

Raihane Ben Lakhal, Hela Ghedira, Hatem Bellaaj, Yosra Ben Youssef, Samia Menif, Zeineb Manai, Manel Bedoui, Amel Lakhal, Fehmi M’Sadek, Moez Elloumi, Abderrahmane Khélif, Neila Ben Romdhane, Mohamed Adnène Laatiri, Tarek Ben Othmen, Balkis Meddeb

ABSTRACT

Data are limited in developing countries regarding the clinicopathologic features and response to therapy of chronic myeloid leukemia (CML) in the era of imatinib (IM). The objective of this study is to report on the clinicoepidemiologic features of CML in Tunisia, to evaluate the long-term outcome of patients in chronic (CP) or accelerated phase (AP) treated with IM 400 mg daily as frontline therapy, and to determine imatinib's efficacy and safety. From October 2002 to December 2014, 410 CML patients were treated with IM in six Tunisian departments of hematology. Response (hematologic, cytogenetic, and molecular responses) and outcome-overall survival (OS), event-free survival (EFS), and progression-free survival (PFS)-were evaluated. The following prognostic factors were analyzed for their impact on the European leukemia net (ELN) response, OS, EFS, and PFS at 5 years: age, sex, leukocyte count, Sokal score, European Treatment and Outcome Study (EUTOS) score, CML phase, time to starting IM, and impact of adverse events. The median age was 45 years (3-85 years). Two hundred ten (51.2%) patients were male. Splenomegaly was present in 322 of the 410 (79%). Additional cytogenetic abnormalities were encountered in 25 (6.3%) patients. At diagnosis, 379 (92.4%) patients were in CP, 31 (7.6%) were in AP. The Sokal risk was low in 87 (22.5%), intermediate in 138 (35.7%), and high in 164 patients (41.9%). The EUTOS risk was low in 217 (74%), and high in 77 (26%) patients. The rates of cumulative complete cytogenetic response (CCyR), major molecular response (MMR), and molecular response 4/5 log (MR4.5) in CP/AP-CML patients were 72, 68.4, and 46.4%, respectively. The median time to reach CCyR, MMR, and MR4.5 was 6 months (3-51), 18 months (3-72), and 24 months (3-100), respectively. According to the ELN criteria, optimal, suboptimal response, and failure were noted in 206 (51.8%), 61 (15.3%), and 125 (31.4%) patients, respectively. Five-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) were 81, 90, and 90%, respectively. By multivariate analysis, AP, high EUTOS risk, and baseline WBC ≥ 150G/l remained independent predictive factors of non-optimal response to IM. The adverse events (AE) of IM were moderate and tolerable. With the caveats that the monitoring of the disease was not optimal, response rates were similar to those reported in previous studies. It is clear to us that improvements should be made in treatment of AP-CML and high Sokal risk group of CP-CML. The frontline use of second-generation tyrosine kinase inhibitor (TKI) is expected to improve the results of the first-line treatment of these high-risk Tunisian patients, but cost and accessibility of this therapy remain the problems in developing countries. More... »

PAGES

597-604

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-017-3224-2

DOI

http://dx.doi.org/10.1007/s00277-017-3224-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100210747

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29305630


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imatinib Mesylate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Accelerated Phase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Chronic-Phase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Patterns, Physicians'", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Splenomegaly", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Burden", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tunisia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Hematology Department, Aziza Othmana University Hospital, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ben Lakhal", 
        "givenName": "Raihane", 
        "id": "sg:person.01031704065.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031704065.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Military Hospital of Tunis", 
          "id": "https://www.grid.ac/institutes/grid.415617.0", 
          "name": [
            "Hematology Department, Military Hospital Tunis, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghedira", 
        "givenName": "Hela", 
        "id": "sg:person.01173676503.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173676503.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hopital Universitaire Hedi Chaker", 
          "id": "https://www.grid.ac/institutes/grid.413980.7", 
          "name": [
            "Hematology Department, Hedi Chaker Hospital, Sfax, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bellaaj", 
        "givenName": "Hatem", 
        "id": "sg:person.01272545747.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272545747.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Farhat Hached", 
          "id": "https://www.grid.ac/institutes/grid.412791.8", 
          "name": [
            "Hematology Department, Farhat Hached Hospital, Sousse, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ben Youssef", 
        "givenName": "Yosra", 
        "id": "sg:person.01233270736.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233270736.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Pasteur de Tunis", 
          "id": "https://www.grid.ac/institutes/grid.418517.e", 
          "name": [
            "Biology, Institut Pasteur, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Menif", 
        "givenName": "Samia", 
        "id": "sg:person.01144150252.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144150252.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital La Rabta", 
          "id": "https://www.grid.ac/institutes/grid.414198.1", 
          "name": [
            "Hematology Department, La Rabta Hospital, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Manai", 
        "givenName": "Zeineb", 
        "id": "sg:person.01303726044.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303726044.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Fatuma Bourguiba Monastir", 
          "id": "https://www.grid.ac/institutes/grid.420157.5", 
          "name": [
            "Hematology Department, Fattouma Bourguiba Hospital, Monastir, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bedoui", 
        "givenName": "Manel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centre national de greffe de moelle osseuse, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lakhal", 
        "givenName": "Amel", 
        "id": "sg:person.0674365474.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674365474.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Military Hospital of Tunis", 
          "id": "https://www.grid.ac/institutes/grid.415617.0", 
          "name": [
            "Hematology Department, Military Hospital Tunis, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u2019Sadek", 
        "givenName": "Fehmi", 
        "id": "sg:person.01075106770.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075106770.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hopital Universitaire Hedi Chaker", 
          "id": "https://www.grid.ac/institutes/grid.413980.7", 
          "name": [
            "Hematology Department, Hedi Chaker Hospital, Sfax, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elloumi", 
        "givenName": "Moez", 
        "id": "sg:person.01056727274.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056727274.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Farhat Hached", 
          "id": "https://www.grid.ac/institutes/grid.412791.8", 
          "name": [
            "Hematology Department, Farhat Hached Hospital, Sousse, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kh\u00e9lif", 
        "givenName": "Abderrahmane", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital La Rabta", 
          "id": "https://www.grid.ac/institutes/grid.414198.1", 
          "name": [
            "Hematology Department, La Rabta Hospital, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ben Romdhane", 
        "givenName": "Neila", 
        "id": "sg:person.014516120011.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014516120011.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Fatuma Bourguiba Monastir", 
          "id": "https://www.grid.ac/institutes/grid.420157.5", 
          "name": [
            "Hematology Department, Fattouma Bourguiba Hospital, Monastir, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laatiri", 
        "givenName": "Mohamed Adn\u00e8ne", 
        "id": "sg:person.0774067574.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774067574.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centre national de greffe de moelle osseuse, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ben Othmen", 
        "givenName": "Tarek", 
        "id": "sg:person.015063534654.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015063534654.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Haematology, Aziza Othmana University Hospital, Tunis, Tunisia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meddeb", 
        "givenName": "Balkis", 
        "id": "sg:person.01355200215.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355200215.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2010.32.0598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007332152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa062867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018371941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21756", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018939501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2010-12-319038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020965449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/clk.2008.n.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020989135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22498", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028507716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clml.2012.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029177922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032191468"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.0779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035509430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.leukres.2010.03.033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036672086"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-03-490128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037321453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-05-501569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037386922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2006-02-005686", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038332915"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/ejh.12453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045027896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.leukres.2010.10.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045774124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1590/s1516-84842005000300005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046444210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beha.2009.07.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047721362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa022457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052596157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5430/jhm.v2n2p25", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072847323"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04", 
    "datePublishedReg": "2018-04-01", 
    "description": "Data are limited in developing countries regarding the clinicopathologic features and response to therapy of chronic myeloid leukemia (CML) in the era of imatinib (IM). The objective of this study is to report on the clinicoepidemiologic features of CML in Tunisia, to evaluate the long-term outcome of patients in chronic (CP) or accelerated phase (AP) treated with IM 400\u00a0mg daily as frontline therapy, and to determine imatinib's efficacy and safety. From October 2002 to December 2014, 410 CML patients were treated with IM in six Tunisian departments of hematology. Response (hematologic, cytogenetic, and molecular responses) and outcome-overall survival (OS), event-free survival (EFS), and progression-free survival (PFS)-were evaluated. The following prognostic factors were analyzed for their impact on the European leukemia net (ELN) response, OS, EFS, and PFS at 5\u00a0years: age, sex, leukocyte count, Sokal score, European Treatment and Outcome Study (EUTOS) score, CML phase, time to starting IM, and impact of adverse events. The median age was 45\u00a0years (3-85\u00a0years). Two hundred ten (51.2%) patients were male. Splenomegaly was present in 322 of the 410 (79%). Additional cytogenetic abnormalities were encountered in 25 (6.3%) patients. At diagnosis, 379 (92.4%) patients were in CP, 31 (7.6%) were in AP. The Sokal risk was low in 87 (22.5%), intermediate in 138 (35.7%), and high in 164 patients (41.9%). The EUTOS risk was low in 217 (74%), and high in 77 (26%) patients. The rates of cumulative complete cytogenetic response (CCyR), major molecular response (MMR), and molecular response 4/5 log (MR4.5) in CP/AP-CML patients were 72, 68.4, and 46.4%, respectively. The median time to reach CCyR, MMR, and MR4.5 was 6\u00a0months (3-51), 18\u00a0months (3-72), and 24\u00a0months (3-100), respectively. According to the ELN criteria, optimal, suboptimal response, and failure were noted in 206 (51.8%), 61 (15.3%), and 125 (31.4%) patients, respectively. Five-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) were 81, 90, and 90%, respectively. By multivariate analysis, AP, high EUTOS risk, and baseline WBC\u2009\u2265\u2009150G/l remained independent predictive factors of non-optimal response to IM. The adverse events (AE) of IM were moderate and tolerable. With the caveats that the monitoring of the disease was not optimal, response rates were similar to those reported in previous studies. It is clear to us that improvements should be made in treatment of AP-CML and high Sokal risk group of CP-CML. The frontline use of second-generation tyrosine kinase inhibitor (TKI) is expected to improve the results of the first-line treatment of these high-risk Tunisian patients, but cost and accessibility of this therapy remain the problems in developing countries.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00277-017-3224-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1018247", 
        "issn": [
          "1269-3286", 
          "1279-8509"
        ], 
        "name": "Annals of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "97"
      }
    ], 
    "name": "Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)", 
    "pagination": "597-604", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1285f169d4890a8cef3d94fcfffd5f92bf6a3080b1fc5d00390a37e4cda377fd"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29305630"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9107334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-017-3224-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100210747"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-017-3224-2", 
      "https://app.dimensions.ai/details/publication/pub.1100210747"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000603.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00277-017-3224-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3224-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3224-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3224-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3224-2'


 

This table displays all metadata directly associated to this object as RDF triples.

341 TRIPLES      21 PREDICATES      72 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-017-3224-2 schema:about N0481c9caa08342bcb5288e4e57a72781
2 N0581ecdbb5a941bea6e66bc92136d895
3 N2e1e1e801f1448ae9426f6c104a3ac1a
4 N38b285f7dfa94fce99c8777cbb7caa5d
5 N39dfa24ee9304744a179d42d29a2fcf3
6 N45205b9764c94f7f94a3f1d12953c4e3
7 N4fcd66a5114342e3881ab9bfec882ef6
8 N61530c1d794744ac9f412347fbddb913
9 N6e7fb74370044fe4ad802f23114f503f
10 N87cba80d261c45aba4bd4ffabe10bc69
11 N97e471d6fbd243b6b9e74d853762b786
12 N9da1b280d109412291a6297589eba47e
13 Naf4f2120a0ef4a3ead3d77e755570662
14 Nba028ef62eeb4777a441070486ea72c2
15 Nbe8b75e25d9d42cca46cbca7ef10b12b
16 Ndbb9a2250316472c81825b320601808f
17 Ndbc4b1f0e9cf40169f44b2be4489c41b
18 Ndc02ed7240c043dbaad823b98b3a22cf
19 Ndd72bead5b5040bf8b02c7e13461db4a
20 Ndfdba8050428461cabb87311230c6ac3
21 Ne5e1ee987a274919b478b4c21b5eddd4
22 Nf2f894c50b874f999339f2c566c9e94b
23 Nfcfa010aa9f645aabcf6fcdaa8a8c5fb
24 Nfd461c70bdf445699bfe354249d1c5e2
25 anzsrc-for:11
26 anzsrc-for:1112
27 schema:author N94174185e74840dbbfb0d3eb4350067d
28 schema:citation https://doi.org/10.1002/cncr.11831
29 https://doi.org/10.1002/cncr.21756
30 https://doi.org/10.1002/cncr.22498
31 https://doi.org/10.1016/j.beha.2009.07.007
32 https://doi.org/10.1016/j.clml.2012.07.009
33 https://doi.org/10.1016/j.leukres.2010.03.033
34 https://doi.org/10.1016/j.leukres.2010.10.027
35 https://doi.org/10.1056/nejmoa022457
36 https://doi.org/10.1056/nejmoa062867
37 https://doi.org/10.1111/ejh.12453
38 https://doi.org/10.1182/blood-2006-02-005686
39 https://doi.org/10.1182/blood-2010-12-319038
40 https://doi.org/10.1182/blood-2013-03-490128
41 https://doi.org/10.1182/blood-2013-05-501569
42 https://doi.org/10.1200/jco.2009.25.0779
43 https://doi.org/10.1200/jco.2010.32.0598
44 https://doi.org/10.1590/s1516-84842005000300005
45 https://doi.org/10.3816/clk.2008.n.036
46 https://doi.org/10.5430/jhm.v2n2p25
47 schema:datePublished 2018-04
48 schema:datePublishedReg 2018-04-01
49 schema:description Data are limited in developing countries regarding the clinicopathologic features and response to therapy of chronic myeloid leukemia (CML) in the era of imatinib (IM). The objective of this study is to report on the clinicoepidemiologic features of CML in Tunisia, to evaluate the long-term outcome of patients in chronic (CP) or accelerated phase (AP) treated with IM 400 mg daily as frontline therapy, and to determine imatinib's efficacy and safety. From October 2002 to December 2014, 410 CML patients were treated with IM in six Tunisian departments of hematology. Response (hematologic, cytogenetic, and molecular responses) and outcome-overall survival (OS), event-free survival (EFS), and progression-free survival (PFS)-were evaluated. The following prognostic factors were analyzed for their impact on the European leukemia net (ELN) response, OS, EFS, and PFS at 5 years: age, sex, leukocyte count, Sokal score, European Treatment and Outcome Study (EUTOS) score, CML phase, time to starting IM, and impact of adverse events. The median age was 45 years (3-85 years). Two hundred ten (51.2%) patients were male. Splenomegaly was present in 322 of the 410 (79%). Additional cytogenetic abnormalities were encountered in 25 (6.3%) patients. At diagnosis, 379 (92.4%) patients were in CP, 31 (7.6%) were in AP. The Sokal risk was low in 87 (22.5%), intermediate in 138 (35.7%), and high in 164 patients (41.9%). The EUTOS risk was low in 217 (74%), and high in 77 (26%) patients. The rates of cumulative complete cytogenetic response (CCyR), major molecular response (MMR), and molecular response 4/5 log (MR4.5) in CP/AP-CML patients were 72, 68.4, and 46.4%, respectively. The median time to reach CCyR, MMR, and MR4.5 was 6 months (3-51), 18 months (3-72), and 24 months (3-100), respectively. According to the ELN criteria, optimal, suboptimal response, and failure were noted in 206 (51.8%), 61 (15.3%), and 125 (31.4%) patients, respectively. Five-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) were 81, 90, and 90%, respectively. By multivariate analysis, AP, high EUTOS risk, and baseline WBC ≥ 150G/l remained independent predictive factors of non-optimal response to IM. The adverse events (AE) of IM were moderate and tolerable. With the caveats that the monitoring of the disease was not optimal, response rates were similar to those reported in previous studies. It is clear to us that improvements should be made in treatment of AP-CML and high Sokal risk group of CP-CML. The frontline use of second-generation tyrosine kinase inhibitor (TKI) is expected to improve the results of the first-line treatment of these high-risk Tunisian patients, but cost and accessibility of this therapy remain the problems in developing countries.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N65ead453ad1d427a919e3288324f97d4
54 N9cf13248d1b549359e115d49162fb4ff
55 sg:journal.1018247
56 schema:name Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)
57 schema:pagination 597-604
58 schema:productId N170f2f385ed3468aa86d4dc3374f1541
59 N2397a0962c6b4cf8afb1bc9978721017
60 Nb0d6e6d538a5452bae9345e53820a275
61 Ncea50ee7e7ad4059bdc2b96a90623ed6
62 Nfb3732a8f65c4cf2967b067e2fcc9d75
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100210747
64 https://doi.org/10.1007/s00277-017-3224-2
65 schema:sdDatePublished 2019-04-10T16:05
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N5389b391a22344e48bbd50530fc15c41
68 schema:url http://link.springer.com/10.1007/s00277-017-3224-2
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N0481c9caa08342bcb5288e4e57a72781 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Child
74 rdf:type schema:DefinedTerm
75 N0581ecdbb5a941bea6e66bc92136d895 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Follow-Up Studies
77 rdf:type schema:DefinedTerm
78 N0b758b9a93244c4594fc6e34bd017f2e rdf:first sg:person.01056727274.50
79 rdf:rest N1e9b5a7268a84f01b4a5a9f121a9c883
80 N170f2f385ed3468aa86d4dc3374f1541 schema:name pubmed_id
81 schema:value 29305630
82 rdf:type schema:PropertyValue
83 N1c70cbe8b79243458b7cb728211ffdb5 schema:name Department of Haematology, Aziza Othmana University Hospital, Tunis, Tunisia
84 rdf:type schema:Organization
85 N1e9b5a7268a84f01b4a5a9f121a9c883 rdf:first N98db6d3a27e24365b3e0e00b83a59314
86 rdf:rest N246e843f57434054b21126911da79b59
87 N1f7f9a38e3f84742b968f4077276a228 rdf:first sg:person.01173676503.48
88 rdf:rest N22324bcc540a4b99a15c91402c0263aa
89 N22324bcc540a4b99a15c91402c0263aa rdf:first sg:person.01272545747.71
90 rdf:rest Nf124da99cd7642daa3d84a5894f40487
91 N2397a0962c6b4cf8afb1bc9978721017 schema:name doi
92 schema:value 10.1007/s00277-017-3224-2
93 rdf:type schema:PropertyValue
94 N246e843f57434054b21126911da79b59 rdf:first sg:person.014516120011.95
95 rdf:rest N5e85b9e0a59b4830a35d759f85bf48ee
96 N2e1e1e801f1448ae9426f6c104a3ac1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Retrospective Studies
98 rdf:type schema:DefinedTerm
99 N329fcea1c19c4378b8f6bdc63ac2b9b3 rdf:first sg:person.01303726044.31
100 rdf:rest N842a14946e9e44e3b714633b9a841b0a
101 N38b285f7dfa94fce99c8777cbb7caa5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Practice Patterns, Physicians'
103 rdf:type schema:DefinedTerm
104 N39dfa24ee9304744a179d42d29a2fcf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Aged, 80 and over
106 rdf:type schema:DefinedTerm
107 N45205b9764c94f7f94a3f1d12953c4e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Imatinib Mesylate
109 rdf:type schema:DefinedTerm
110 N4fcd66a5114342e3881ab9bfec882ef6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Male
112 rdf:type schema:DefinedTerm
113 N5389b391a22344e48bbd50530fc15c41 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N597cb802f681484ba687a3a61e1f70b9 schema:name Hematology Department, Aziza Othmana University Hospital, Tunis, Tunisia
116 rdf:type schema:Organization
117 N5e85b9e0a59b4830a35d759f85bf48ee rdf:first sg:person.0774067574.94
118 rdf:rest N6671aa6304564eb0a4d4ae944b2a51c4
119 N61530c1d794744ac9f412347fbddb913 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 N65ead453ad1d427a919e3288324f97d4 schema:volumeNumber 97
123 rdf:type schema:PublicationVolume
124 N6671aa6304564eb0a4d4ae944b2a51c4 rdf:first sg:person.015063534654.80
125 rdf:rest N96331e85931240468f3d1e64756449d2
126 N6e7fb74370044fe4ad802f23114f503f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Adult
128 rdf:type schema:DefinedTerm
129 N7f1d269a5cce43e18003f8b9d417e460 rdf:first sg:person.01075106770.68
130 rdf:rest N0b758b9a93244c4594fc6e34bd017f2e
131 N842a14946e9e44e3b714633b9a841b0a rdf:first N91071b3e5148494090ddd09103a8c81d
132 rdf:rest Ndffab6937ed14f509f1173f419029767
133 N852f6b81b4544ca2a4e2025605e49a5e schema:name Centre national de greffe de moelle osseuse, Tunis, Tunisia
134 rdf:type schema:Organization
135 N87cba80d261c45aba4bd4ffabe10bc69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Leukemia, Myeloid, Chronic-Phase
137 rdf:type schema:DefinedTerm
138 N91071b3e5148494090ddd09103a8c81d schema:affiliation https://www.grid.ac/institutes/grid.420157.5
139 schema:familyName Bedoui
140 schema:givenName Manel
141 rdf:type schema:Person
142 N94174185e74840dbbfb0d3eb4350067d rdf:first sg:person.01031704065.26
143 rdf:rest N1f7f9a38e3f84742b968f4077276a228
144 N96331e85931240468f3d1e64756449d2 rdf:first sg:person.01355200215.69
145 rdf:rest rdf:nil
146 N97e471d6fbd243b6b9e74d853762b786 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Child, Preschool
148 rdf:type schema:DefinedTerm
149 N98db6d3a27e24365b3e0e00b83a59314 schema:affiliation https://www.grid.ac/institutes/grid.412791.8
150 schema:familyName Khélif
151 schema:givenName Abderrahmane
152 rdf:type schema:Person
153 N9cf13248d1b549359e115d49162fb4ff schema:issueNumber 4
154 rdf:type schema:PublicationIssue
155 N9da1b280d109412291a6297589eba47e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Prognosis
157 rdf:type schema:DefinedTerm
158 Na484068d3235407d9255bc4856048827 rdf:first sg:person.01144150252.98
159 rdf:rest N329fcea1c19c4378b8f6bdc63ac2b9b3
160 Naf4f2120a0ef4a3ead3d77e755570662 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Tumor Burden
162 rdf:type schema:DefinedTerm
163 Nb0d6e6d538a5452bae9345e53820a275 schema:name readcube_id
164 schema:value 1285f169d4890a8cef3d94fcfffd5f92bf6a3080b1fc5d00390a37e4cda377fd
165 rdf:type schema:PropertyValue
166 Nba028ef62eeb4777a441070486ea72c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Splenomegaly
168 rdf:type schema:DefinedTerm
169 Nbe8b75e25d9d42cca46cbca7ef10b12b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Protein Kinase Inhibitors
171 rdf:type schema:DefinedTerm
172 Ncea50ee7e7ad4059bdc2b96a90623ed6 schema:name nlm_unique_id
173 schema:value 9107334
174 rdf:type schema:PropertyValue
175 Ndbb9a2250316472c81825b320601808f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Aged
177 rdf:type schema:DefinedTerm
178 Ndbc4b1f0e9cf40169f44b2be4489c41b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Humans
180 rdf:type schema:DefinedTerm
181 Ndc02ed7240c043dbaad823b98b3a22cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Survival Analysis
183 rdf:type schema:DefinedTerm
184 Ndd72bead5b5040bf8b02c7e13461db4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Antineoplastic Agents
186 rdf:type schema:DefinedTerm
187 Ndfdba8050428461cabb87311230c6ac3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Tunisia
189 rdf:type schema:DefinedTerm
190 Ndffab6937ed14f509f1173f419029767 rdf:first sg:person.0674365474.29
191 rdf:rest N7f1d269a5cce43e18003f8b9d417e460
192 Ne5e1ee987a274919b478b4c21b5eddd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Leukemia, Myeloid, Accelerated Phase
194 rdf:type schema:DefinedTerm
195 Nf124da99cd7642daa3d84a5894f40487 rdf:first sg:person.01233270736.60
196 rdf:rest Na484068d3235407d9255bc4856048827
197 Nf251262cb34046cbb432def3306bf191 schema:name Centre national de greffe de moelle osseuse, Tunis, Tunisia
198 rdf:type schema:Organization
199 Nf2f894c50b874f999339f2c566c9e94b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Adolescent
201 rdf:type schema:DefinedTerm
202 Nfb3732a8f65c4cf2967b067e2fcc9d75 schema:name dimensions_id
203 schema:value pub.1100210747
204 rdf:type schema:PropertyValue
205 Nfcfa010aa9f645aabcf6fcdaa8a8c5fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Young Adult
207 rdf:type schema:DefinedTerm
208 Nfd461c70bdf445699bfe354249d1c5e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Female
210 rdf:type schema:DefinedTerm
211 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
212 schema:name Medical and Health Sciences
213 rdf:type schema:DefinedTerm
214 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
215 schema:name Oncology and Carcinogenesis
216 rdf:type schema:DefinedTerm
217 sg:journal.1018247 schema:issn 1269-3286
218 1279-8509
219 schema:name Annals of Hematology
220 rdf:type schema:Periodical
221 sg:person.01031704065.26 schema:affiliation N597cb802f681484ba687a3a61e1f70b9
222 schema:familyName Ben Lakhal
223 schema:givenName Raihane
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031704065.26
225 rdf:type schema:Person
226 sg:person.01056727274.50 schema:affiliation https://www.grid.ac/institutes/grid.413980.7
227 schema:familyName Elloumi
228 schema:givenName Moez
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056727274.50
230 rdf:type schema:Person
231 sg:person.01075106770.68 schema:affiliation https://www.grid.ac/institutes/grid.415617.0
232 schema:familyName M’Sadek
233 schema:givenName Fehmi
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075106770.68
235 rdf:type schema:Person
236 sg:person.01144150252.98 schema:affiliation https://www.grid.ac/institutes/grid.418517.e
237 schema:familyName Menif
238 schema:givenName Samia
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144150252.98
240 rdf:type schema:Person
241 sg:person.01173676503.48 schema:affiliation https://www.grid.ac/institutes/grid.415617.0
242 schema:familyName Ghedira
243 schema:givenName Hela
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173676503.48
245 rdf:type schema:Person
246 sg:person.01233270736.60 schema:affiliation https://www.grid.ac/institutes/grid.412791.8
247 schema:familyName Ben Youssef
248 schema:givenName Yosra
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233270736.60
250 rdf:type schema:Person
251 sg:person.01272545747.71 schema:affiliation https://www.grid.ac/institutes/grid.413980.7
252 schema:familyName Bellaaj
253 schema:givenName Hatem
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272545747.71
255 rdf:type schema:Person
256 sg:person.01303726044.31 schema:affiliation https://www.grid.ac/institutes/grid.414198.1
257 schema:familyName Manai
258 schema:givenName Zeineb
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303726044.31
260 rdf:type schema:Person
261 sg:person.01355200215.69 schema:affiliation N1c70cbe8b79243458b7cb728211ffdb5
262 schema:familyName Meddeb
263 schema:givenName Balkis
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355200215.69
265 rdf:type schema:Person
266 sg:person.014516120011.95 schema:affiliation https://www.grid.ac/institutes/grid.414198.1
267 schema:familyName Ben Romdhane
268 schema:givenName Neila
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014516120011.95
270 rdf:type schema:Person
271 sg:person.015063534654.80 schema:affiliation N852f6b81b4544ca2a4e2025605e49a5e
272 schema:familyName Ben Othmen
273 schema:givenName Tarek
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015063534654.80
275 rdf:type schema:Person
276 sg:person.0674365474.29 schema:affiliation Nf251262cb34046cbb432def3306bf191
277 schema:familyName Lakhal
278 schema:givenName Amel
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674365474.29
280 rdf:type schema:Person
281 sg:person.0774067574.94 schema:affiliation https://www.grid.ac/institutes/grid.420157.5
282 schema:familyName Laatiri
283 schema:givenName Mohamed Adnène
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774067574.94
285 rdf:type schema:Person
286 https://doi.org/10.1002/cncr.11831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032191468
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1002/cncr.21756 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018939501
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1002/cncr.22498 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028507716
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1016/j.beha.2009.07.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047721362
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1016/j.clml.2012.07.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029177922
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1016/j.leukres.2010.03.033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036672086
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1016/j.leukres.2010.10.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045774124
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1056/nejmoa022457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052596157
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1056/nejmoa062867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018371941
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1111/ejh.12453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045027896
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1182/blood-2006-02-005686 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038332915
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1182/blood-2010-12-319038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020965449
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1182/blood-2013-03-490128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037321453
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1182/blood-2013-05-501569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037386922
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1200/jco.2009.25.0779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035509430
315 rdf:type schema:CreativeWork
316 https://doi.org/10.1200/jco.2010.32.0598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007332152
317 rdf:type schema:CreativeWork
318 https://doi.org/10.1590/s1516-84842005000300005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046444210
319 rdf:type schema:CreativeWork
320 https://doi.org/10.3816/clk.2008.n.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020989135
321 rdf:type schema:CreativeWork
322 https://doi.org/10.5430/jhm.v2n2p25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072847323
323 rdf:type schema:CreativeWork
324 https://www.grid.ac/institutes/grid.412791.8 schema:alternateName Hôpital Farhat Hached
325 schema:name Hematology Department, Farhat Hached Hospital, Sousse, Tunisia
326 rdf:type schema:Organization
327 https://www.grid.ac/institutes/grid.413980.7 schema:alternateName Hopital Universitaire Hedi Chaker
328 schema:name Hematology Department, Hedi Chaker Hospital, Sfax, Tunisia
329 rdf:type schema:Organization
330 https://www.grid.ac/institutes/grid.414198.1 schema:alternateName Hôpital La Rabta
331 schema:name Hematology Department, La Rabta Hospital, Tunis, Tunisia
332 rdf:type schema:Organization
333 https://www.grid.ac/institutes/grid.415617.0 schema:alternateName Military Hospital of Tunis
334 schema:name Hematology Department, Military Hospital Tunis, Tunis, Tunisia
335 rdf:type schema:Organization
336 https://www.grid.ac/institutes/grid.418517.e schema:alternateName Institut Pasteur de Tunis
337 schema:name Biology, Institut Pasteur, Tunis, Tunisia
338 rdf:type schema:Organization
339 https://www.grid.ac/institutes/grid.420157.5 schema:alternateName Hospital Fatuma Bourguiba Monastir
340 schema:name Hematology Department, Fattouma Bourguiba Hospital, Monastir, Tunisia
341 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...